Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

Frequently Asked Questions

Veklury for the Commercial Marketplace after October 1, 2020

  1. The agreement between the U.S. Government, Gilead Sciences, Inc. (the manufacturer of Veklury (remdesivir)) and AmerisourceBergen (the distributer of Veklury (remdesivir)) ends September 30, 2020. After October 1, will the U.S. Government continue to oversee the allocation and distribution of Veklury (remdesivir)?
  2. After October 1, will state health departments play a role in allocating or distributing Veklury (remdesivir)?
  3. According to the FDA’s emergency use authorization (EUA) for Veklury (remdesivir), the U.S. government is required to oversee the distribution and allocation of Veklury (remdesivir). Did the EUA change?
  4. The. U.S. government secured 500,000 treatment courses of commercially available Veklury (remdesivir) between July 6 and September 30, 2020, but only distributed 160,981 to states/territories and federal agencies. Why didn’t the government distribute all 500,000 treatment courses, and what happened to the remaining product??
  5. How much will hospitals pay for Veklury (remdesivir) now that it has fully entered the commercial marketplace? Will hospitals see a price increase?
  6. Will patients be charged for Veklury (remdesivir) as part of their hospital stay?
  7. How can hospitals order Veklury (remdesivir) now that the U.S. Government is no longer overseeing the drug’s allocation and distribution?
  8. Will AmerisourceBergen continue to serve as the sole distributor of Veklury (remdesivir)?
  9. Now that the U.S. Government no longer oversees the allocation and distribution of Veklury (remdesivir), is there a limit to the amount of Veklury (remdesivir) hospitals can purchase?
  10. How will the U.S. Government ensure a sufficient domestic supply of Veklury (remdesivir) continues to exist?
  11. I’m interested in learning more about the U.S. Government’s role in the allocation and distribution of Veklury (remdesivir) prior to October 1, 2020. How can I find out more?



  1. The agreement between the U.S. Government, Gilead Sciences, Inc. (the manufacturer of Veklury) and AmerisourceBergen (the distributer of Veklury) ends September 30, 2020. After October 1, will the U.S. Government continue to oversee the allocation and distribution of Veklury?

From May 4 – September 30, 2020, the U.S. Department of Health and Human Services’ (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) worked to ensure the only drug authorized for emergency use to treat hospitalized patients with suspected or laboratory-confirmed COVID-19 was allocated fairly across states and U.S. territories. The U.S. Government’s (USG) agreement to secure commercially available Veklury (remdesivir) for use in American hospitals ended on September 30. As of October 1, USG oversight of the allocation and distribution of Veklury (remdesivir) is no longer required since supply is greater than demand by U.S. hospitals. As such, hospitals will work directly with the distributor to purchase Veklury (remdesivir) just as they do with other COVID-19 associated drugs.


  1. After October 1, will state health departments play a role in allocating or distributing Veklury?

State/territorial health departments are no longer required to play a role in the allocation and distribution of Veklury after September 30, 2020.


  1. According to the FDA’s emergency use authorization (EUA) for Veklury, the U.S. government is required to oversee the distribution and allocation of Veklury. Did the EUA change?

Yes; the EUA for Veklury (remdesivir) was updated October 1, 2020. The current EUA does not require U.S. government oversight of the allocation and distribution of Veklury (remdesivir). Hospitals can now order directly from the distributor in unrestricted amounts.


  1. The. U.S. government secured 500,000 treatment courses of commercially available Veklury (remdesivir) between July 6 and September 30, 2020, but only distributed 160,981 to states/territories and federal agencies. Why didn’t the government distribute all 500,000 treatment courses, and what happened to the remaining product?

Between July 6 and September 30, 2020, HHS/ASPR allocated 100 percent (500,000 treatment courses) of the commercially available Veklury (remdesivir) provided through the agreement with Gilead Sciences, Inc. and AmerisourceBergen. Of this amount, state and territorial health departments accepted 84 percent of their allocations (423,765 treatment courses); however, only 32 percent (160,981 treatment courses) of the total allocation was actually purchased by hospitals in their jurisdictions. Over the course of the project, ASPR allocated over 700,000 treatment courses, which included the reallocation of 200,000 treatment courses that were not initially accepted by state and territorial health departments.

Of the remaining approximately 339,000 treatment courses, a portion was purchased by the U.S. Government for placement into the Strategic National Stockpile; the remaining portion was released back to Gilead Sciences, Inc. for commercial sale.

 


  1. How much will hospitals pay for Veklury (remdesivir) now that it has fully entered the commercial marketplace? Will hospitals see a price increase?

There will be no change to the price of the drug for American hospitals after September 30. Hospitals will continue to pay no more than Gilead’s wholesale acquisition cost, approximately $3,200 per treatment course ($520 per vial).


  1. Will patients be charged for Veklury (remdesivir) as part of their hospital stay?

Generally, patients do not pay directly for hospital-administered drugs like Veklury (remdesivir); rather, for Medicare and most private insurers, the drug’s cost is incorporated into payments made by the insurer, such as Medicare paying for the drug through a diagnostic-related group.

Private insurers (including Humana, Cigna, UnitedHealth Group, and the Blue Cross Blue Shield system) committed to waive cost-sharing payments for treatment related to COVID-19 for plan members, and HHS is using a portion of the $100 billion Provider Relief Fund to reimburse healthcare providers, at Medicare rates, for COVID-related treatment of the uninsured.


  1. How can hospitals order Veklury (remdesivir) now that the U.S. Government is no longer overseeing the drug’s allocation and distribution?

As of October 1, hospitals can order Veklury (remdesivir) just as they do other COVID-19 associated drugs. In an effort to help ensure continued efficient distribution of the drug, Gilead Sciences, Inc. will use AmerisourceBergen as the sole distributor of Veklury (remdesivir) at least through December 2020. As such, hospitals can order Veklury (remdesivir) directly from AmerisourceBergen. Any hospital that does not currently have an account with AmerisourceBergen can establish one by visiting their online ordering portal. Additionally, AmerisourceBergen is available to answer questions or concerns from purchasing hospitals to assist in making this process a smooth transition. AmerisourceBergen can be contacted directly at 877-746-6273 or via email at Veklury (remdesivir)@amerisourcebergen.com.


  1. Will AmerisourceBergen continue to serve as the sole distributor of Veklury (remdesivir)?

Yes, in an effort to help ensure continued efficient distribution of the drug, Gilead Sciences, Inc. will use AmerisourceBergen as the sole distributor of Veklury (remdesivir) at least through December 2020. As such, hospitals can order Veklury (remdesivir) directly from AmerisourceBergen. Any hospital that does not currently have an account with AmerisourceBergen can establish one by visiting their online ordering portal. Additionally, AmerisourceBergen is available to answer questions or concerns from purchasing hospitals to assist in making this process a smooth transition. AmerisourceBergen can be contacted directly at 877-746-6273 or via email at Veklury (remdesivir)@amerisourcebergen.com.


  1. Now that the U.S. Government no longer oversees the allocation and distribution of Veklury (remdesivir), is there a limit to the amount of Veklury (remdesivir) hospitals can purchase?

No, there are no restrictions regarding the amount of Veklury (remdesivir) hospitals can purchase after October 1. At this time, Gilead Sciences, Inc. reports that the company has a sufficient supply of Veklury (remdesivir) on hand and has increased their manufacturing capacity to ensure there will be enough Veklury (remdesivir) to meet the needs of U.S. hospitals. For additional information, please contact Gilead Sciences, Inc. at 1-800-GILEAD-5 or via email at public_affairs@gilead.com.


  1. How will the U.S. Government ensure a sufficient domestic supply of Veklury (remdesivir) continues to exist?

Drug manufactures must alert the U.S. Food and Drug Administration (FDA) regarding potential drug shortages, including any shortages that might compromise the supply chain of Veklury (remdesivir). If a shortage is identified, the FDA works closely with drug manufacturers to prevent or reduce the impact of such shortages.

Additionally, HHS-ASPR will continue to monitor COVID-19 patient data submitted by hospitals through the HHS Protect data collection platform, including data elements previously used to help determine Veklury (remdesivir) allocations:

  • Previous day’s new adult admissions for confirmed COVID-19
  • Previous day’s new adult admissions for suspected COVID-19
  • Total adults hospitalized for COVID-19 (suspected and confirmed)
  • Total hospitalized for COVID-19 (confirmed only)
  • Total adults in Intensive Care Unit with COVID-19 (suspected and confirmed)
  • Total adults in Intensive Care Unit with COVID-19 (confirmed)

It should also be noted that between July 6 and September 30, 2020, only 160,982 of the 500,000 treatment courses secured per the agreement with Gilead Sciences, Inc. and AmerisourceBergen were purchased by American hospitals. Of the remaining 339,000 treatment courses, a portion was purchased by the U.S. Government for placement into the Strategic National Stockpile.


  1. I’m interested in learning more about the U.S. Government’s role in the allocation and distribution of Veklury (remdesivir) prior to October 1, 2020. How can I find out more?

For more information about HHS/ASPR’s role in the allocation and distribution of Veklury (remdesivir), including information on its allocation strategy; the data used to determine allocation amounts by state/territory; and the number of cases of Veklury (remdesivir) allocated to each state and territory between May 4 and September 30, see U.S. Government’s Allocation and Distribution of Veklury (remdesivir) (May 4, 2020 through September 30, 2020).


  
>>> Back to Veklury Overview <<<

  • This page last reviewed: October 01, 2020